Introduction
============

Neuroendocrine gastrointestinal tumors constitute a heterogeneous group of tumors and share a common phenotype, with positive immunostaining for the neuroendocrine markers chromogranin A and synaptophysin, among others. Neuron-specific enolase and CD56 are often, but not always, positive ([@b1-mco-0-0-1624]). Pure small cell carcinomas of the gastrointestinal tract are in fact poorly differentiated, high-grade gastro-enteropancreatic neuroendocrine carcinomas ([@b2-mco-0-0-1624]). Primary small cell gastric carcinomas (SCGC) account for 15--20% of all gastric neuroendocrine tumors ([@b3-mco-0-0-1624]), 0.1% of extra-pulmonary small cell carcinomas (ESCC) and \<0.1% of all gastric cancer cases ([@b4-mco-0-0-1624],[@b5-mco-0-0-1624]), and occur primarily in males (5.4:1 ratio) ([@b6-mco-0-0-1624]).

Small cell carcinoma of the gastrointestinal tract was first described in 1952 ([@b7-mco-0-0-1624]), and primary SCGC was initially reported in 1976 ([@b6-mco-0-0-1624]). Since then, only a few hundred cases of SCGC have been reported, mainly in Asian populations ([@b6-mco-0-0-1624],[@b8-mco-0-0-1624]--[@b10-mco-0-0-1624]). SCGC is characterized by early, widespread metastases and a poor overall prognosis ([@b11-mco-0-0-1624]). Due to the rarity of the disease, and therefore the inability to conduct prospective and randomized clinical trials, clear and thorough guidelines for SCGC treatment have not yet been established. Nevertheless, the similarities between SCGC and small cell lung carcinoma (SCLC) with respect to their histopathology, molecular biology and clinical course have resulted in the use of the same therapeutic strategies for SCGC and SCLC ([@b6-mco-0-0-1624],[@b11-mco-0-0-1624]).

Herein, two cases of primary SCGC in young Caucasian males are presented, along with a review of the literature. Informed consent was obtained from both patients for whom identifying information is included in this article.

Case reports
============

### Case 1

In December 2014, a 44-year old male patient was admitted to the 251 General Air Force Hospital in Athens (Greece), after a 2-month history of intermittent and persistent epigastric pain. The patient was afebrile with stable vital signs, no reported weight loss and the clinical examination revealed nothing else of note. The medical history was insignificant and the results of the laboratory tests were within the normal range, including the tumor biomarkers carcinoembryonic antigen (CEA), cancer antigen (CA) 19-9 and α-fetoprotein (α-FP).

Esophagogastroduodenoscopy revealed a large fungating mass in the gastro-esophageal junction extending from the cardia of the stomach. The biopsy revealed a high-grade small cell carcinoma, without evidence of *Helicobacter pylori* gastritis ([Fig. 1A](#f1-mco-0-0-1624){ref-type="fig"}). Immunohistochemistry (IHC) revealed that the tumor cells were positive for synaptophysin, chromogranin, cytokeratin 8 and 18, AE3 and CD117, and negative for CD56, cytokeratin 7 and 20 and CEA, whereas almost all cells (95--100%) were Ki-67 positive ([Fig. 1B and C](#f1-mco-0-0-1624){ref-type="fig"}).

Computed tomography (CT) of the thorax was negative, but a CT scan of the abdomen and pelvis revealed a round 18 mm lesion at the gastro-esophageal junction with regional thickening of the gastric wall around the cardia of the stomach. Two enlarged lymph nodes were also identified at the right groin and at the upper third of the right external iliac chain, measuring 25 and 15 mm, respectively.

Positron emission tomography (PET)/CT revealed increased fludeoxyglucose (FDG) uptake along the gastro-esophageal junction and cardia of the stomach \[maximum standardized uptake value (SUV~max~), 10.4\], at one paraaortic lymph node (14 mm with SUV~max~, 10.2) and at multiple pelvic (right ileac and inguinal) lymph nodes ([Fig. 2A](#f2-mco-0-0-1624){ref-type="fig"}). Furthermore, a highly hypermetabolic (SUV~max~, 24.2) nodule of 29 mm was detected at the right thyroid lobe, and fine needle aspiration revealed a papillary thyroid cancer.

The Multidisciplinary Team (MDT) of the Institution (251 General Air Force Hospital) proposed systemic chemotherapy with standard etoposide/cisplatin combination. The patient received six cycles of chemotherapy with cisplatin 70 mg/m^2^ on day 1 and etoposide 100 mg/m^2^ on days 1, 2 and 3, every 3 weeks, with excellent tolerance for 4 months (from December 2014 until April 2015). After the second chemotherapy cycle, a control PET/CT scan revealed a significant metabolic partial response ([Fig. 2B](#f2-mco-0-0-1624){ref-type="fig"}) with only the two residual right external ileac lymph nodes (one of 12 mm in diameter, with SUV~max~, 5.5; one of 9 mm in diameter, with SUV~max~, 2.2). One month following treatment completion, imaging studies with whole body CT scans indicated a complete clinical response. Further treatment with external radiotherapy was selected due to better local disease control. The patient received 5,040 cGy in 28 fractions of 180 cGy to the gastro-esophageal junction region, to the celiac, paraaortic, common ileac, internal ileac, external ileac and inguinal lymph node regions. Radiation was administered using intensity-modulated radiation therapy with concurrent cisplatin (40 mg/m^2^) every 7 days for 3 weeks.

Approximately two months following the completion of radiotherapy, the patient was underwent a total thyroidectomy for papillary thyroid cancer and received post-operative radioiodine therapy. A total of 20 months following treatment completion, the patient remains in complete remission and asymptomatic; an esophagogastroduodenoscopy with blind biopsies, as well as imaging studies that included a whole body PET/CT scan, did not reveal any residual disease.

### Case 2

In October 2013, a 45-year old male was admitted to the Iaso General Hospital in Athens, with a 3-week history of dysphagia and pain in the upper abdomen. The patient was afebrile and asymptomatic between meals. Clinical examination was normal and the results of laboratory tests, including CEA, CA 19-9 and α-FP, were within the normal range. Upper gastrointestinal endoscopy revealed an ulcerative tumor in the gastro-esophageal junction. The histological report indicated a high-grade small cell carcinoma positive for synaptophysin and CD56, but negative for chromogranin ([Fig. 1D](#f1-mco-0-0-1624){ref-type="fig"}). Furthermore, the cells were CK7(+), CK18(+), CK20(−) and Ki-67(+) (80--90% of the cells) ([Fig. 1E and F](#f1-mco-0-0-1624){ref-type="fig"}).

Thoracic and abdominal CT scans were negative for metastatic disease, and a radical gastrectomy with D2 lymph node dissection was performed. Pathological examination of the surgical specimen confirmed the diagnosis of a small cell carcinoma with metastatic involvement in six lymph nodes of the lesser omentum, in one of the left gastric artery and in one of the hepatic artery. The tumor invaded the muscularis propria but did not penetrate the serosa. Thus, the TNM classification was T2N1M0 according to the European Neuroendocrine Tumor Society ([@b12-mco-0-0-1624]), and T2N3M0 stage IIIA according to the American Joint Committee on Cancer (AJCC) ([@b12-mco-0-0-1624]).

At 2 months following surgery, the patient was referred to the 1st Department of Medical Oncology and received 6 cycles of chemotherapy with etoposide (100 mg/m^2^ on days 1, 2 and 3) and cisplatin (60 mg/m^2^ on day 1) every 3 weeks, for 4 months and without any treatment modifications. During the last cycle of chemotherapy, the patient experienced an acute thoracic pain; a subsequent CT scan and MRI of the mediastinum revealed a mass measuring 3.4×2.5 cm at the lower left posterior mediastinum. An endoscopic ultrasound (EUS) confirmed this finding and a whole body PET/CT scan indicated increased FDG uptake along the mediastinal lesion (SUV~max~, 8) without other hypermetabolic localization.

Based on these findings, a metastasectomy was attempted, but the patient only underwent subtotal surgical resection of the mediastinal lesion as the mass had infiltrated the adjacent thoracic aorta. External image guided radiation therapy (5,580 cGy in 28 fractions) with concurrent carboplatin (AUC=2) every week for 5 weeks was subsequently administered, resulting in disease stabilization. A total of 3 months later, thoracic and abdominal CT scans revealed massive disease progression with multiple lung and liver metastases and subcutaneous nodules. A further 2 cycles of weekly paclitaxel (100 mg/m^2^ on days 1, 8 and 15 every 28 days), in combination with bevacizumab (10 mg/kg every 15 days), were administered without success. The patient succumbed to disease almost 3 months later due to acute respiratory failure causes by a lung infection and disease progression, 20.2 months after the initial diagnosis.

Discussion
==========

Epidemiology. Extra-pulmonary small cell carcinomas are rare types of tumors, 18.2% of which are localized in the upper gastrointestinal tract ([@b13-mco-0-0-1624]). SCGC accounts for 0.1--1% of all GI malignancies ([@b11-mco-0-0-1624]), whereas primary SCGC represents \~0.1% of all gastric cancer cases ([@b4-mco-0-0-1624],[@b5-mco-0-0-1624]). Wu *et al* ([@b6-mco-0-0-1624]) retrospectively evaluated 205 patients with SCGC from January 1999 until December 2012, all from China, and reported a predominance of SCGC in males (male to female ratio, 5.4:1) ([@b6-mco-0-0-1624],[@b11-mco-0-0-1624]).

Molecular biology and pathology. To the best of our knowledge, there are no published data regarding the molecular basis of SCGC pathogenesis and its molecular biology. However, the available data, though limited, from cases of esophageal small cell cancer, suggest a similar molecular profile for gastrointestinal and pulmonary small cell cancer, with universal high rates of proliferative activity and telomerase inactivation, p53 overexpression (65--83 and 90% respectively) and pRb inactivation (67--95 and 90% respectively). K-Ras mutations (0.17 and 0% respectively) are rare and the loss of p16 expression (33 and 10% respectively) is infrequent ([@b11-mco-0-0-1624]). The Ki67 (MIB-1) index in SCGC is, by definition, \>20%, ranging from 30--95.5% ([@b14-mco-0-0-1624]). The pathological characteristics and the immunohistochemical features of SCGC are essentially identical to those of SCLC ([@b4-mco-0-0-1624],[@b6-mco-0-0-1624],[@b11-mco-0-0-1624],[@b15-mco-0-0-1624]--[@b21-mco-0-0-1624]). However, almost half of SCGC cases are 'mixed' or 'combined' tumors, comprised of SCC and nonSCC components ([@b6-mco-0-0-1624],[@b11-mco-0-0-1624],[@b22-mco-0-0-1624],[@b23-mco-0-0-1624]).

Staging and prognosis. In 2007, the European Neuroendocrine Tumour Society (ENETS) proposed a staging system of gastrointestinal neuroendocrine neoplasms, adapted for the several primary sites: i) Stomach; ii) duodenum, ampulla of Vater, proximal jejunum; iii) lower jejunum; ileum; iv) pancreas; and v) colon and rectum. It takes into account the following: i) Depth of invasion; ii) tumor size; and iii) the presence of regional lymph nodes or distant metastases ([@b14-mco-0-0-1624],[@b24-mco-0-0-1624]). This staging system was later endorsed and modified by the AJCC ([@b12-mco-0-0-1624]).

Patient survival depends on the treatment approach selected. Patients who received curative surgery experienced an \~6-fold increase in survival compared with those who did not (46.45 and 7.65 months respectively) ([@b25-mco-0-0-1624],[@b26-mco-0-0-1624]); in addition, patients who received post-operative chemotherapy survived ≥2× longer (48.50 vs. 19.00 months) ([@b27-mco-0-0-1624]). The median overall survival time for patients with SCGC is \~18.50 months ([@b6-mco-0-0-1624]), with 1-, 2- and 5-year survival rates of 66.75, 37.13 and 20.10%, respectively ([@b25-mco-0-0-1624]--[@b29-mco-0-0-1624]).

Treatment. Wu *et al* ([@b6-mco-0-0-1624]) reported that 97.6% (200) of the 205 studied Chinese patients with SCGC underwent surgical resection, leading to a median overall survival time of 46.45 months (range, 10.00--63.00 months). Although patients who received adjuvant chemotherapy obtained a relatively prolonged survival time; thus, curative surgery can be regarded as a standard treatment for locoregional non-metastatic SCGC ([@b6-mco-0-0-1624],[@b27-mco-0-0-1624]).

Post-operative chemotherapy is considered a standard treatment and several regimens are in clinical use ([Table I](#tI-mco-0-0-1624){ref-type="table"}) ([@b11-mco-0-0-1624]); however, platinum based chemotherapy forms the backbone of treatment for early and metastatic disease ([@b30-mco-0-0-1624]). Huang *et al* ([@b27-mco-0-0-1624]) demonstrated a survival advantage of almost 30 months for surgery plus chemotherapy (48.5 months) vs. surgery alone (19 months) ([@b27-mco-0-0-1624]). Pre-operative chemotherapy with the same regimen is also a rational option ([@b11-mco-0-0-1624],[@b31-mco-0-0-1624]). Cisplatin plus irinotecan is an alternative first line treatment ([@b32-mco-0-0-1624]), but there is no standard regimen for second line therapy. Brain metastases are infrequent and prophylactic cranial irradiation is not recommended ([@b33-mco-0-0-1624]).

Although concurrent or sequential chemoradiotherapy is associated with satisfactory results in patients with gastrointestinal small cell carcinoma, particularly esophageal-SCC, data regarding the effect of radiotherapy on SCGC are currently limited. In the larger published series of patients with SCGC by Wu *et al* ([@b6-mco-0-0-1624]) only two patients received radiotherapy.

The two patient cases presented herein have been treated according to current practice but had opposing outcomes. The patient with disseminated disease at diagnosis (case 1) was evaluated in the MDT and it was decided to administer first-line chemotherapy with the standard etoposide/cisplatin regimen. Chemotherapy resulted in a major objective response that was followed by radiotherapy. It is considered, as in the case of SCLC, that involved-field radiation may further disease control, thus explaining the favorable clinical outcome of the patient. Conversely, the second patient did not have the opportunity to be discussed in the MDT and underwent a 'curative' gastrectomy for locoregional disease with post-operative chemotherapy applied after a 2-month delay. However, it should be noted that the pre-surgical staging of the disease was inadequate as there was no more detailed evaluation of the regional lymph nodes status by either a PET/CT scan or a laparoscopy and lymph node sampling. Such an evaluation could change the therapeutic plan administering first systemic chemotherapy followed by, depending on the results, either curative surgery or involved-field radiotherapy. On the other hand, it cannot be excluded that the 2-month delay in the administration of chemotherapy was an important adverse contributor to the patient\'s clinical outcome and the early disease dissemination based on the assumption of the possible presence of occult metastatic disease at the time of initial diagnosis.

To conclude, primary SCGC is a rare type of disease in Caucasians, and the two cases discussed indicate the treatment challenges presented by this disease. SCGC is aggressive with poor prognosis and currently small retrospective case series are the main source of data for this malignancy, which shares the same histopathological, molecular, clinical and treatment characteristics with SCLC. Careful evaluation of each patient\'s case by the MDT and a multimodal therapeutic approach are strongly recommended for this disease, with platinum-based chemotherapy regimens to represent the standard of care. The MDT must determine for each individual case the optimal therapeutic strategy, and critically evaluate the role and the sequence of local treatments (surgery or radiotherapy) administered alone or in combination with chemotherapy. This is particularly important considering the absence of prospective randomized studies as the only data currently available are from treated patients.
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![Case 1: (A) Hematoxylin and eosin staining, magnification ×40; (B) synaptophysin (×10); (C) Ki-67 staining. Case 2: Histological appearance of the gastric small cell carcinoma. (D) Hematoxylin and eosin staining, magnification ×20; the tumor cells were also positive for (E) synaptophysin (×20) and (F) almost universally for Ki-67 (×20).](mco-09-01-0011-g00){#f1-mco-0-0-1624}

![(A) Case 1: PET/CT at diagnosis revealing the primary tumor, one hypermetabolic paraortic and pelvic (right ileac and inguinal) lymph nodes. (B). Case 1: PET/CT scan following two chemotherapy cycles. Corresponding slices to the findings presented in (A). PET/CT, positron emission tomography/computed tomography.](mco-09-01-0011-g01){#f2-mco-0-0-1624}

###### 

Single case reports and retrospective series of patients with small cell gastric cancer.

                                                                             Initial treatment                                                                                               
  ----------------------------------------------- -------------------- ----- ------------------- ------------------ ----------- ------------------------------------------------------------ -------------
  Wu *et al* ([@b6-mco-0-0-1624]), 2015           Review article       205   Yes (n=200)         Yes (n=139)        Yes (n=2)   N/A                                                          N/A
  Namikawa *et al* ([@b15-mco-0-0-1624]), 2005    Case report          1     Yes                 Yes                --          CDDP+VP-16                                                   \>36 months
  Frances *et al* ([@b23-mco-0-0-1624]), 2013     Case report          1     --                  Yes                Yes         CDDP+VP-16                                                   7.5 months
  Dong *et al* ([@b25-mco-0-0-1624]), 2010        Series of patients   23    Yes                 N/A                --          N/A                                                          17.7 months
  Huang *et al* ([@b26-mco-0-0-1624]), 2013       Series of patients   41    Yes (n=25)          Yes (n=25)         --          CDDP/Carboplatin+VP-16                                       19 months
  Liu *et al* ([@b28-mco-0-0-1624]), 2013         Series of patients   17    Yes (n=17)          Yes (n=11)         --          CDDP/Carboplatin+VP-16                                       13 months
  Kou *et al* ([@b29-mco-0-0-1624]), 2013         Series of patients   42    Yes                 Yes                --          5-FU+LOHP                                                    25 months
  Terada *et al* ([@b34-mco-0-0-1624]), 2013      Case report          1     --                  Yes                --          CDDP based                                                   N/A
  Kuo *et al* ([@b35-mco-0-0-1624]), 2009         Case report          1     Yes                 Yes                --          CDDP/Carboplatin+VP-16                                       17 months
  Kai Xin *et al* ([@b36-mco-0-0-1624]), 2014     Case report          1     Yes                 Yes                --          CPT-11+LOHP                                                  N/A
  Iwamuro *et al* ([@b37-mco-0-0-1624]), 2009     Case report          2     --                  Yes                --          Carboplatin+VP-16-                                           14.5 months
  Koide *et al* ([@b38-mco-0-0-1624]), 2007       Case report          1     Yes                 Yes                --          CDDP+S-1                                                     N/A
  Hussein *et al* ([@b39-mco-0-0-1624]), 1990     Case report          1     Yes                 Yes                --          N/A                                                          10
  Hamano *et al* ([@b40-mco-0-0-1624]), 2007      Case report          1     Yes                 --                 --          --                                                           N/A
  Funahashi *et al* ([@b41-mco-0-0-1624]), 2013   Case report          1     Yes                 Yes                --          CDDP+CPT-11                                                  12 months
  Tanemura *et al* ([@b42-mco-0-0-1624]), 2002    Case report          1     Yes                 --                 --          --                                                           \>43 months
  Moise *et al* ([@b43-mco-0-0-1624]), 2010       Case report          1     --                  --                 --          --                                                           0.5 months
  Cioppa *et al* ([@b44-mco-0-0-1624]), 2007      Case report          1     Yes                 Yes                --          CDDP based CMT                                               15 months
  Okita *et al* ([@b45-mco-0-0-1624]), 2011       Series of patients   22    Yes                 Yes (at relapse)   --          CDDP+CPT-11                                                  22.6 months
  Peng *et al* ([@b46-mco-0-0-1624]), 2013        Series of patients   27    Yes (n=27)          Yes (n=22)         --          CDDP+VP-16 (n=12) Cyclophosphamide+Doxorubicin+CDDP (n=10)   10 months
  Nakamura *et al* ([@b47-mco-0-0-1624]), 2005    Case report          1     Yes                 Yes                --          Carboplatin+Epirubin+VP-16+5-FU                              \>36 months
  Onoyama *et al* ([@b48-mco-0-0-1624]), 2011     Case report          1     --                  Yes                --          CDDP+CPT-11                                                  \>28 months

OS, overall survival; CDDP, cisplatin; VP-16, etoposide; 5-FU, fluorouracil; LOHP, oxaliplatin; CMT, chemotherapy; CPT-11, irinotecan; S-1, tegafur/gimeracil/oteracil.
